3,4-双((4-甲氧基苄基)氧基)-N-(2-(吡咯烷-1-基)乙基)苯甲酰胺 | 1225208-49-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-双((4-甲氧基苄基)氧基)-N-(2-(吡咯烷-1-基)乙基)苯甲酰胺
• 英文名称: 3,4-bis((4-methoxybenzyl)oxy)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide
• 英文别名: 3,4-bis[(4-methoxyphenyl)methoxy]-N-(2-pyrrolidin-1-ylethyl)benzamide
• CAS: 1225208-49-0
• 化学式: C₂₉H₃₄N₂O₅
• 分子量: 490.599
• InChiKey: RTGZCRJKOPNHHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,4-双((4-甲氧基苄基)氧基)-N-(2-(吡咯烷-1-基)乙基)苯甲酰胺 、 (4-methoxyphenyl)methyl (6R,7R)-3-(iodomethyl)-7-[[2-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]acetyl]amino]-5,8-dioxo-5lambda4-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 在 乙酰氯 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  CEPHALOSPORIN HAVING CATECHOL GROUP

  摘要：

  公开号：

  EP2341053B1
• 作为产物：
  描述：

  1-(2-氨乙基)吡咯烷 、 3,4-bis(4-Methoxybenzyloxy)benzoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以83%的产率得到3,4-双((4-甲氧基苄基)氧基)-N-(2-(吡咯烷-1-基)乙基)苯甲酰胺
  参考文献：
  名称：

  Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

  摘要：

  The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.06.014

文献信息

• US9238657B2
  申请人：——

  公开号：US9238657B2

  公开（公告）日：2016-01-19
• Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
  作者：Toshiaki Aoki、Hidenori Yoshizawa、Kenji Yamawaki、Katsuki Yokoo、Jun Sato、Shinya Hisakawa、Yasushi Hasegawa、Hiroki Kusano、Masayuki Sano、Hideki Sugimoto、Yasuhiro Nishitani、Takafumi Sato、Masakatsu Tsuji、Rio Nakamura、Toru Nishikawa、Yoshinori Yamano

  DOI：10.1016/j.ejmech.2018.06.014

  日期：2018.7

  The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection. (C) 2018 Elsevier Masson SAS. All rights reserved.
• CEPHALOSPORIN HAVING CATECHOL GROUP
  申请人：Shionogi & Co., Ltd.

  公开号：EP2341053B1

  公开（公告）日：2016-01-13